Line of therapy: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by drcancer

Line of therapy Introduction (What it is)

Line of therapy is a clinical term for the sequence of cancer treatments a person receives over time.
It labels each planned “round” of treatment, such as first-line treatment and second-line treatment.
It is commonly used in oncology visits, tumor boards, clinical notes, and clinical trials.
It helps teams communicate what has been tried, what worked, and what may come next.

Why Line of therapy used (Purpose / benefits)

Cancer care often unfolds in steps rather than as a single treatment. A person may start with one approach, then change strategies if the cancer does not respond, comes back (recurs), or becomes resistant. Line of therapy provides a structured way to describe that treatment journey.

Key purposes and benefits include:

Clarity in communication: “First-line” has a shared meaning across oncology teams, helping clinicians coordinate care across medical oncology, surgery, radiation oncology, pathology, radiology, and supportive care.
Treatment planning and sequencing: It supports decisions about what to use now versus what to reserve for later, based on goals (tumor control, cure intent, symptom relief) and what options remain.
Consistent documentation: Medical records, insurance authorizations, and referrals often rely on whether a therapy is being used in an earlier or later line.
Clinical trial eligibility: Many trials specify “treatment-naïve” (no prior systemic therapy) or require a certain number of prior lines.
Patient understanding: It can help patients and families track where they are in the overall plan, why a change is being recommended, and what “next steps” usually mean in oncology.

Importantly, a Line of therapy is not a single drug or procedure. It is a framework for organizing therapies over time, tailored to the cancer type, stage, biology, and the person’s overall health—details that vary by cancer type and stage.

Indications (When oncology clinicians use it)

Clinicians use the concept of Line of therapy in many routine and complex situations, including:

When starting initial treatment for a newly diagnosed cancer (first-line setting)
When cancer does not respond to an initial regimen (refractory disease)
When cancer returns after treatment (recurrent disease)
When cancer progresses during treatment (progressive disease)
When selecting therapy for metastatic/advanced disease, where multiple treatment steps may be expected
When discussing maintenance therapy after an initial response
When planning treatment around surgery or radiation (neoadjuvant/adjuvant pathways)
When assessing clinical trial options that depend on prior treatments
When documenting prior exposure to drugs (for example, prior platinum chemotherapy or prior immunotherapy)

Contraindications / when it’s NOT ideal

Because Line of therapy is a classification and communication tool—not a medication or procedure—it does not have contraindications in the usual medical sense. However, relying on “lines” can be less ideal or potentially misleading in certain circumstances:

Curative single-modality plans: Some early-stage cancers are treated with one definitive approach (such as surgery alone), where “lines” may add little value.
Complex combined-modality care: When therapies are intentionally combined (for example, concurrent chemoradiation), calling this “one line” versus “two lines” can vary by clinician and case.
Rapidly changing clinical status: If urgent symptom control is needed (for example, spinal cord compression), immediate local measures may take priority over line labeling.
Non-standard sequences: When a person receives multiple short courses, re-challenges, or intermittent treatments, the boundaries between lines can be unclear.
Cross-over therapies: Switching from one drug to another within the same class (or within the same regimen) may or may not be counted as a new line, depending on context.
Hematologic malignancies with distinct phases: In leukemias and some lymphomas, “induction,” “consolidation,” and “maintenance” phases may be more informative than “first-line/second-line” alone.

In these situations, clinicians often use more precise wording such as treatment phase, regimen, intent (curative vs palliative), and reason for change (toxicity, progression, recurrence).

How it works (Mechanism / physiology)

Line of therapy does not act on the body directly, so it has no pharmacologic mechanism of action and no direct physiology. Instead, it describes the clinical pathway of cancer management—how treatments are selected, sequenced, and evaluated.

At a high level, the framework reflects common realities of tumor biology and cancer treatment:

Tumor sensitivity and resistance: Many cancers respond to an initial therapy but later develop resistance through genetic changes, pathway adaptations, or selection of resistant cancer cell populations. A later Line of therapy is often chosen to address a new resistance pattern or a different target.
Disease burden and distribution: Localized disease may be approached with local therapies (surgery, radiation), while systemic disease often needs systemic therapies (chemotherapy, targeted therapy, endocrine therapy, immunotherapy). The “line” may refer specifically to systemic therapy, while local treatments can be layered in for symptom control or consolidation.
Host factors: Organ function, performance status (how well someone can carry out daily activities), comorbidities, and prior side effects influence which therapies are safe and feasible in each line.
Treatment goals and time course: The “onset and duration” concept applies to the response to a given regimen rather than the line itself. Some therapies work quickly to shrink tumors; others are intended for longer-term control. Duration varies by cancer type and stage, regimen, and patient tolerance.

In practice, each Line of therapy is a decision point: select a therapy based on evidence and patient-specific factors, administer it, measure response, and either continue, adjust, or move to another line.

Line of therapy Procedure overview (How it’s applied)

Line of therapy is not a single procedure. It is applied as a structured way to plan and document care over time. A typical workflow looks like this:

Evaluation/exam – Review diagnosis, symptoms, functional status, and prior treatments (if any). – Clarify the treatment goal (curative intent, disease control, symptom relief, or supportive care).
Imaging/biopsy/labs – Confirm cancer type and key features (histology, grade, receptor status, molecular markers when relevant). – Establish baseline measurements (tumor size on scans, blood counts, organ function).
Staging – Determine disease extent (localized, locally advanced, metastatic) using standard staging systems where applicable. – Identify urgent issues that may require immediate local intervention (for example, threatened organ function).
Treatment planning – Choose an initial regimen or approach consistent with guidelines and patient factors. – Decide how response will be monitored (imaging, tumor markers, symptom tracking, physical exams).
Intervention/therapy – Deliver the planned treatment (systemic therapy, surgery, radiation, or combined approaches). – Provide supportive care to manage side effects and maintain function.
Response assessment – Evaluate whether the cancer is responding, stable, or progressing. – Document tolerability and any dose adjustments, delays, or discontinuations.
Follow-up/survivorship – If the cancer is controlled or in remission, plan surveillance and long-term side effect monitoring. – If progression occurs, reassess goals and select the next Line of therapy or consider clinical trials or supportive-focused care, depending on the case.

The “line” label is typically assigned when a treatment plan is initiated and may be updated if the plan changes due to toxicity, lack of benefit, or new clinical information.

Types / variations

Line of therapy can be described in different ways depending on cancer type, treatment setting, and clinical intent. Common variations include:

First-line, second-line, third-line (and beyond)
First-line: The initial standard systemic therapy used for a given setting (for example, metastatic disease).
Second-line: Treatment given after the first-line regimen is ineffective or no longer works.
Later lines: Subsequent options used after multiple prior therapies, often with increasing emphasis on balancing potential benefit with side effects and quality of life.
Treatment-naïve vs previously treated
“Treatment-naïve” may mean no prior systemic therapy for the current stage of disease, but definitions vary by clinician and case (for example, prior adjuvant therapy vs metastatic therapy).
Curative-intent vs palliative-intent pathways
In some cancers, early lines are used with curative intent (for example, neoadjuvant therapy followed by surgery), while later lines may be palliative (aimed at controlling disease and symptoms).
Neoadjuvant, adjuvant, and maintenance contexts
Neoadjuvant: Therapy before surgery or definitive radiation to shrink the tumor or address micrometastatic disease.
Adjuvant: Therapy after definitive local treatment to reduce recurrence risk.
Maintenance: Ongoing lower-intensity therapy after initial response to prolong control in selected cancers.
Systemic vs local therapy considerations
“Line of therapy” most often refers to systemic therapy lines. Local therapies (surgery, radiation, ablation) may be part of the same overall plan but are not always counted as a “line” in the same way.
Solid tumors vs hematologic malignancies
In solid tumors, lines often map to changes in systemic regimens for advanced disease.
In hematologic cancers, the concept is used, but phase-based terms (induction, consolidation, transplant, maintenance) are also common and sometimes more precise.
Adult vs pediatric oncology
Pediatric protocols may follow standardized multi-phase regimens where “line” terminology is used differently or less prominently.
Inpatient vs outpatient delivery
Many first-line regimens are outpatient, while some intensive therapies (or complications) require inpatient care. The line classification is independent of setting.

Pros and cons

Pros:

Helps clinicians communicate treatment history quickly and consistently.
Supports structured decision-making about sequencing and next options.
Common language for clinical trial design and eligibility criteria.
Useful for documenting prior drug exposure and resistance patterns.
Can help patients track the overall treatment journey and reasons for change.

Cons:

Definitions can vary (what “counts” as a new line is not always uniform).
May oversimplify complex combined-modality plans or phase-based regimens.
Can be confusing when switching drugs for toxicity versus progression.
Does not capture treatment intent, dose intensity, or supportive care needs by itself.
May feel overly linear despite real-world care involving pauses, re-challenges, or local therapies.

Aftercare & longevity

Aftercare is not determined by the Line of therapy label itself, but by the treatments within each line and the person’s overall plan. In general, what affects outcomes and the “longevity” of benefit from a given line includes:

Cancer type and stage: Outcomes and typical sequencing differ widely across cancers and between early-stage and metastatic disease.
Tumor biology: Molecular markers, growth rate, and mechanisms of resistance influence how long a therapy remains effective.
Treatment intensity and tolerability: Dose reductions, delays, or discontinuation for side effects can affect effectiveness and quality of life; the balance varies by clinician and case.
Response depth and durability: Some responses are rapid but short-lived; others are slower and more sustained. This depends on the therapy and tumor biology.
Supportive care and symptom management: Managing nausea, fatigue, pain, infections, nutrition issues, and mental health can help people stay on therapy and maintain function.
Comorbidities and organ function: Heart, lung, liver, kidney, and bone marrow reserve can shape which lines are feasible and safe.
Follow-up and surveillance: Imaging and lab monitoring schedules vary by cancer type and treatment; monitoring is used to assess response and detect progression or recurrence.
Rehabilitation and survivorship care: Physical therapy, occupational therapy, lymphedema care, sexual health support, and return-to-work planning may be relevant, depending on treatment effects.
Access and logistics: Transportation, caregiving support, medication access, and infusion capacity can influence real-world treatment continuity.

This is general information, not a plan for any individual. Follow-up strategies and the meaning of “success” differ across cancers and patient goals.

Alternatives / comparisons

Line of therapy is a way to organize treatment options, not an alternative to them. The practical comparisons are usually between strategies within a given line or decisions about whether to move to a new line.

Common comparisons include:

Observation/active surveillance vs starting a new line
In selected slow-growing cancers or low-burden situations, careful monitoring may be considered instead of immediate treatment. Whether that is appropriate varies by cancer type and stage.
Continuing the current regimen vs switching
If imaging shows stable disease and side effects are manageable, clinicians may continue the same line.
If the cancer progresses or toxicity is limiting, switching therapy (often counted as a new line) may be considered.
Local therapy (surgery/radiation) vs systemic therapy
Local therapies treat disease in a specific area and may be used for cure in localized disease or for symptom relief in advanced disease.
Systemic therapy circulates throughout the body and is commonly used when disease is metastatic or at high risk of spread.
Chemotherapy vs targeted therapy vs immunotherapy vs endocrine therapy
These categories differ in how they affect cancer cells and the immune system, and in side effect patterns.
Which one is used in first-line or later lines depends on tumor biology (for example, actionable targets), prior treatments, and overall goals.
Standard care vs clinical trials
Clinical trials may offer access to new therapies or new combinations, often with specific eligibility tied to prior lines.
Standard care is typically based on established evidence and guideline-supported regimens. Trial participation suitability varies by clinician and case.
Best supportive care alongside or instead of further lines
Supportive (palliative) care can be provided at any point and focuses on symptoms, function, and quality of life.
In some later-line situations, the balance of potential benefit versus side effects may lead to a stronger focus on symptom-directed care rather than additional anti-cancer therapy.

Line of therapy Common questions (FAQ)

Q: Does “Line of therapy” mean my cancer is worse?
Not necessarily. The term simply describes order: first-line is the first planned treatment for a given setting, and later lines come after changes for progression, recurrence, or intolerance. Some people receive multiple lines over time because their cancer behaves like a chronic illness, while others may not need more than one approach. Meaning varies by cancer type and stage.

Q: What is the difference between a “line” and a “regimen”?
A regimen is the specific treatment plan (for example, a particular drug combination and schedule). A Line of therapy is the broader category for where that regimen fits in the sequence (first-line, second-line, and so on). A single line may include adjustments to the regimen, depending on tolerability and clinician judgment.

Q: If a drug is stopped due to side effects, does that count as a new line?
It depends on context. Some clinicians count a switch for toxicity as a new line, while others consider it a modification within the same line if the intent and general approach remain similar. Documentation often clarifies the reason for the change (toxicity vs progression).

Q: Will a new Line of therapy be painful or require anesthesia?
Line of therapy itself does not involve pain because it is a classification. However, treatments within a line can involve procedures (biopsies, port placement, surgery) or side effects that vary widely. Whether anesthesia is used depends on the specific procedure, not the “line” label.

Q: How long does a Line of therapy last?
There is no single duration. A line may continue as long as it is helping control the cancer and side effects are manageable, or it may be stopped earlier if the cancer progresses or toxicity is significant. Duration varies by cancer type and stage, treatment approach, and individual response.

Q: Is later-line treatment less safe?
Safety depends on the specific therapy, dose, organ function, and overall health rather than the line number alone. Later lines may be chosen when options are fewer or when prior treatments have affected bone marrow or organ reserve, which can change risk-benefit considerations. Clinicians typically monitor closely for side effects throughout all lines.

Q: What side effects should I expect with different lines?
Side effects are linked to the specific treatments used (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, surgery, radiation). Earlier lines may use more established regimens, while later lines may involve different drugs with different toxicities or supportive care needs. Side effect profiles and severity vary by clinician and case.

Q: How does cost relate to Line of therapy?
Costs often depend on the type of therapy (infusion vs oral medication), setting (inpatient vs outpatient), supportive medications, imaging, and insurance policies. Some coverage decisions consider whether a therapy is being used in a certain line (for example, after another option has been tried). Exact costs and coverage vary widely.

Q: Can I work, drive, or exercise during a Line of therapy?
Many people continue some usual activities during treatment, but this depends on the therapy, side effects (fatigue, infection risk, neuropathy), and job demands. Activity guidance is individualized and may change during a line if blood counts drop or symptoms occur. Discussing practical limitations is a routine part of oncology care.

Q: How does Line of therapy affect fertility or pregnancy planning?
Fertility impact depends on the specific treatment, dose, and timing, not the line number. Some therapies can affect ovaries, testes, or hormonal function, and some are not compatible with pregnancy. Oncology teams often address fertility preservation and reproductive health early, especially before starting therapies known to carry risk.